Vaccine expert Moderna (Ribonucleic acid) Thursday morning reported the financial results for the third quarter of fiscal year 2020. Let’s jot down basic financial news, and then turn to the vaccine that everyone wants to hear:
From a financial point of view, the third quarter was a weird quarter for Moderna. On the one hand, the surge in income from grants related to the COVID-19 pandemic caused income to surge 830% to US$157.9 million. But on the other hand, spending has also skyrocketed-by 166% to $393 million.
And, because $393 million was more than the loss of $157.9 million, Moderna lost money.
a lot of money.
To be precise, US$0.59 per share-59% higher than the loss in the third quarter of 201
On the bright side, Moderna has attracted $1.2 billion in customer deposits for its mRNA-1273 coronavirus vaccine so far this year, with free cash inflow of $718.5 million. By the end of the quarter, Moderna had accumulated $4 billion in cash reserves, and there was nothing to say.
Now, the main event is: Coronavirus.
Moderna confirmed that it has fully recruited 30,000 patients to participate in the phase 3 clinical trial of mRNA-1273.
The management stated that the preliminary data on the effectiveness of mRNA-1273 is “positive” and that the vaccine has proven to be well tolerated at all ages and can induce[ing] It has a fast and strong immune response to SARS-CoV-2. “If the vaccine proves to be at least 75% effective, the company hopes to release the trial’s “first interim” data in November. For effectiveness considerations, the second round of data may arrive as early as December or even January.
After participating in the proceeds of the conference call, Needham analyst Alan Carr observed that the FDA may grant an emergency use authorization for Moderna to begin distributing mRNA-1273 during this period (that is, December 2020). By then, Moderna said it will have produced 20 million doses of the vaccine and can start distribution immediately. Carl still believes that it is prudent not to expect any revenue from the sales of mRNA-1273 this year, but to postpone this prospect until 2021-but it is expected that sales in 2020 will reach $2 billion.
What does this mean for stocks? Carr believes that despite how much revenue Moderna gets from mRNA-1273, or how fast (or how much profit),” COVID-19 Vaccine News [alone will suffice to] Promote the stock into 2021″. Even after that, the analyst still believes that the stock has “long-term value.” He set the target price of the stock as a “buy” and set its target price at $94. click here)
In contrast, JP Morgan Chase analyst Cory Kasimov (Cory Kasimov) basically agreed with Carl’s analysis of the timeline and set a target price of $89, but not much lower than Carl. Still believe that it is necessary to maintain a “cautious” attitude. Perform a short-term evaluation of Moderna stock and assign the stock a “neutral” rating. (To watch Kasimov’s track record, click here)
Where is the other place on the street of the vaccine manufacturer? TipRanks analysis shows that mRNA is “buy”, which seems mostly bullish. Of the 11 analysts tracked in the past three months, 9 are bullish on stocks, while 1 is on the sidelines and 1 is bearish. The stock’s target price is $98.60, with a potential return rate of nearly 46%. (See MRNA stock analysis on TipRanks)
To find great ideas for coronavirus stocks with attractive valuations, visit TipRanks’ “Best Stocks to Buy”, a newly launched tool that brings together all of TipRanks’ stock insights.
Disclaimer: The views expressed in this article are only those of the main analyst. The content is for reference only. Before making any investment, it is very important to conduct your own analysis.